Palvella Therapeutics (PVLA) Change in Accured Expenses (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Change in Accured Expenses of -$900000.0 for Q1 2026, up 69.07% year-over-year from -$532317.1 in Q1 2025, and down 408.22% quarter-over-quarter from $292000.0 in Q4 2025.
Powered by 
Analysis
Palvella Therapeutics (PVLA) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Change in Accured Expenses for 8 consecutive years, with -$900000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 69.07% year-over-year to -$900000.0; the TTM figure through Mar 2026 stood at $710000.0 (up 133.08% YoY), while the FY2025 annual figure was -$1.3 million, down 223.81% from the prior year.
- Change in Accured Expenses slipped to -$900000.0 in Q1 2026 per PVLA's latest filing, from $292000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $801000.0 in Q3 2025 and bottomed at -$2.9 million in Q1 2025.
- Historically, Change in Accured Expenses has averaged -$127777.8 across 3 years, with a median of $292000.0 in 2025.
- On a YoY basis, Change in Accured Expenses climbed as much as 181.56% in 2025 and fell as far as 1117.48% in 2025.
- Palvella Therapeutics' Change in Accured Expenses stood at -$358000.0 in 2024, then soared by 181.56% to $292000.0 in 2025, then sank by 408.22% to -$900000.0 in 2026.
- Business Quant data shows PVLA's Change in Accured Expenses at -$900000.0 in Q1 2026, $292000.0 in Q4 2025, and $801000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - | 1.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.49 Mn |
| Mar 31, 2026 | -900,000.00 |
| Dec 31, 2025 | 292,000.00 |
| Sep 30, 2025 | 801,000.00 |
| Jun 30, 2025 | 517,000.00 |
| Mar 31, 2025 | -2.91 Mn |
| Dec 31, 2024 | -358,000.00 |
| Sep 30, 2024 | 383,000.00 |
| Jun 30, 2024 | 739,000.00 |
| Mar 31, 2024 | 286,000.00 |
| Dec 31, 2017 | 1.01 Mn |
| Sep 30, 2017 | -1.29 Mn |
| Jun 30, 2017 | 3.14 Mn |
| Mar 31, 2017 | -805,903.00 |
| Dec 31, 2016 | 923,955.00 |
| Sep 30, 2016 | 558,137.00 |
| Jun 30, 2016 | 37,871.00 |
| Mar 31, 2016 | 543,037.00 |
| Dec 31, 2015 | 365,748.00 |
| Sep 30, 2015 | 160,068.00 |